EP1487408A1 - Topische zusammensetzung auf basis von ionenaustauscherharzen, insbesondere zur behandlung von erythemen - Google Patents

Topische zusammensetzung auf basis von ionenaustauscherharzen, insbesondere zur behandlung von erythemen

Info

Publication number
EP1487408A1
EP1487408A1 EP03738198A EP03738198A EP1487408A1 EP 1487408 A1 EP1487408 A1 EP 1487408A1 EP 03738198 A EP03738198 A EP 03738198A EP 03738198 A EP03738198 A EP 03738198A EP 1487408 A1 EP1487408 A1 EP 1487408A1
Authority
EP
European Patent Office
Prior art keywords
topical composition
composition according
erythemas
exchange resins
ion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03738198A
Other languages
English (en)
French (fr)
Inventor
Jack Auzerie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ellipse Pharmaceuticals SAS
Original Assignee
Ellipse Pharmaceuticals SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ellipse Pharmaceuticals SAS filed Critical Ellipse Pharmaceuticals SAS
Publication of EP1487408A1 publication Critical patent/EP1487408A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Definitions

  • the present invention relates to a topical composition based on ion exchange resins such as colestyramine, in particular for the treatment of diaper rash in pediatrics.
  • Acute diarrhea which affects many children, especially children under the age of five, often requires treatment to avoid secondary infections and to relieve children of the pain and itching it causes.
  • these bile salts which are acids lower the skin pH and induce erythema.
  • these bile salts have surface-active properties, so that the layer of sebum which is naturally protective, is eliminated.
  • colestyramine is a basic synthetic anion exchange resin which has a strong affinity for bile salts and forms with them an insoluble complex.
  • 1 gram of colestyramine can absorb up to two grams of bile salts. It is a fine white hygroscopic powder, almost insoluble in water, alcohol, chloroform and ether. In a 1% solution, the pH is between 4 and 6.
  • the present invention relates to a composition including at least one ion exchange resin, in particular colestyramine as well as a pH regulator. Indeed, in a completely relevant way, the regulator makes it possible to increase the pH to allow an optimized absorption of bile salts by ion exchange resins.
  • a basic composition according to the present invention comprises the following elements:
  • This composition results in a thick paste.
  • Trials are conducted on subjects with secondary dermatitis as a condition
  • the thick colestyramine paste is applied 4 times a day to the area corresponding substantially to the area covered by a diaper.
  • the medical observation is conducted for each application.
  • a regression of the lesions is noted after 2 to 7 days.
  • the composition allows a local physiological rebalancing following the appearance of irritant dermatitis.
  • the pH regulators can also be chosen from: monopotassium phosphate, disodium phosphate, sodium acetate, ammonium acetate, sodium citrate, citric acid, disodium tetraborate, boric acid , amino acids like lysine, leucine, alanine, methyl p ⁇ r ⁇ hydroxybenzo ⁇ te, propyl p ⁇ r ⁇ hydroxybenzo ⁇ te, sodium benzo ⁇ te.
  • galenical formulations in the form of creams or talc are given below.
  • Labraf il trade name of oleic macrogolglycerides
  • Tefose 63 trade name of PEG-6-32 Stearate and glycol stearate. / Cream with 10% colestyramine and sodium dihydrogen phosphate
  • composition can also be considered for application directly to external supports in direct contact with the areas to be treated, such as diapers for infants, children and the elderly.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP03738198A 2002-03-26 2003-03-26 Topische zusammensetzung auf basis von ionenaustauscherharzen, insbesondere zur behandlung von erythemen Withdrawn EP1487408A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0203729A FR2837710B1 (fr) 2002-03-26 2002-03-26 Composition topique a base de resines echangeuses d'ions, notamment pour le traitement des erythemes
FR0203729 2002-03-26
PCT/FR2003/000948 WO2003080025A1 (fr) 2002-03-26 2003-03-26 Composition topique a base de resines echangeuses d'ions, notamment pour le traitement des erythemes

Publications (1)

Publication Number Publication Date
EP1487408A1 true EP1487408A1 (de) 2004-12-22

Family

ID=27839185

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03738198A Withdrawn EP1487408A1 (de) 2002-03-26 2003-03-26 Topische zusammensetzung auf basis von ionenaustauscherharzen, insbesondere zur behandlung von erythemen

Country Status (6)

Country Link
US (1) US20050220755A1 (de)
EP (1) EP1487408A1 (de)
AU (1) AU2003244715A1 (de)
CA (1) CA2480007A1 (de)
FR (1) FR2837710B1 (de)
WO (1) WO2003080025A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2947276B1 (fr) * 2009-06-24 2012-10-26 Seppic Sa Composition cosmetique a base de resines echangeuses d'ions chargees avec des lipoaminoacides
DE102022103062A1 (de) * 2022-02-09 2023-08-10 Dietrich Seidel Produkte zur Bakterientoxinbindung und -Elimination bei der Behandlung von Wunden und entzündlichen Hautveränderungen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2919230A (en) * 1953-10-29 1959-12-29 Rohm & Haas Hydrophilic base therapeutic compositions comprising cation-exchange resin
US4851392A (en) * 1985-02-05 1989-07-25 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
ATE180968T1 (de) * 1991-12-20 1999-06-15 Hoechst Ag Polyaspartamidderivate als adsorptionsmittel für gallensäuren, mit gallensäuren beladene polyaspartamidderivate und verfahren zu deren herstellung sowie deren anwendung als arzneimittel
WO2000018316A2 (en) * 1998-09-25 2000-04-06 Alcon Laboratories, Inc. Sustained release, and comfortable ophthalmic composition and method for ocular therapy
AU7363700A (en) * 1999-09-21 2001-04-24 Alcon Laboratories, Inc. Use of fatty acid/amino acid soaps to enhance antimicrobial effectiveness of topical pharmaceutical compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO03080025A1 *

Also Published As

Publication number Publication date
AU2003244715A1 (en) 2003-10-08
WO2003080025A1 (fr) 2003-10-02
FR2837710A1 (fr) 2003-10-03
FR2837710B1 (fr) 2005-07-08
US20050220755A1 (en) 2005-10-06
CA2480007A1 (fr) 2003-10-02

Similar Documents

Publication Publication Date Title
US20230240984A1 (en) Dimethyl sulfoxide (dmso) and methylsulfonylmethane (msm) formulations to treat osteoarthritis
C Szepietowski et al. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study
JP5538434B2 (ja) 皮膚疾患を治療または予防するための、アベルメクチンまたはミルベマイシンとアドレナリン受容体との組合せ
WO2008140200A1 (en) External compositions for the skin
AU2393701A (en) Pharmaceutical and cosmetic carrier or composition for topical application
US20140154342A1 (en) Sandalwood oil and its uses related to skin disorders
DE3438455A1 (de) L-lysin- und l-histidinpyruvat
GB1594314A (en) Medicine for the treatment of acne
FR2460135A1 (fr) Composition a usage externe a base de colostrum
US5674539A (en) Method of treating skin and composition
CA2533591A1 (en) Method for treatment of sores and lesions of the skin
EP1032378B1 (de) Verwendung eines gemischs aus einem diol und einer alpha-hydroxysäure zur behandlung hyperkeratotischer hauterkrankungen
EP1487408A1 (de) Topische zusammensetzung auf basis von ionenaustauscherharzen, insbesondere zur behandlung von erythemen
JP2003089629A (ja) 新規化粧品、新規外用剤及び新規浴剤の製造方法
FR2894820A1 (fr) Compositions comprenant au moins un compose retinoide et au moins un compose anti-irritant et leurs utilisations
FR2646603A1 (fr) Composition nettoyante
FR2793795B1 (fr) Isomeres de tetramides du complexe de gadolinium de l'acide (1,4,7,10-tetrazacyclododecane)1,4,7,10-tetra(2-glutarique) leur procede de preparation et leur application en imagerie medicale
EP1965786B1 (de) Zusammensetzungen mit mindestens einer retinoid-verbindung und mindestens einer reizhemmenden verbindung sowie anwendungen davon
EP0075523A1 (de) Arzneimittel auf der Basis von Algenextrakten und deren Zusammensetzungen
EP2104496A2 (de) Verwendung von nepafenac oder derivaten davon zur behandlung von hauterkrankungen in verbindung mit einem keratinisationsleiden einschliesslich einer immunallergischen entzündungskomponente
FR2558058A1 (fr) Compositions dermatologiques a usage topique externe, a base de metronidazole utiles pour le traitement de l'acne
FR2694694A1 (fr) Composition active pour le traitement du psoriasis, notamment le psoriasis du cuir chevelu.
JP3047179B1 (ja) 皮膚化粧料
McKinnon et al. Calcipotriol (Dovonex) scalp solution in the treatment of scalp psoriasis: comparative efficacy with 1% coal tar/1% coconut oil/0.5% salicylic acid (Capasal) shampoo, and long-term experience
Jasmin et al. Assessment of the efficacy of a 3% chlorhexidine shampoo in the control of elevated cutaneous Malassezia populations and associated clinical signs (Malassezia dermatitis) in dogs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040920

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

17Q First examination report despatched

Effective date: 20061127

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070411